drugset / Trial / NCT04415164
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
Phase 4
Unknown
480 enrolled
Dongzhimen Hospital, Beijing
Tianjin University of Traditional Chinese Medicine · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim is to assess the effects and harms of Xueshuantong lyophilized powder versus placebo in patients with acute ischemic stroke when initiated within 72 hours of symptom onset.
Timeline
- Start
- 2020-09-29
- Primary completion
- 2022-10-31
- Completion
- 2023-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Xueshuantong | Unknown | 500 mg | Intravenous |